Publications by authors named "Barry C Jones"

Claim this Profile
F
Further Considerations Towards an Effective and Efficient Oncology Drug Discovery DMPK Strategy.
Beth Williamson, Nicola Colclough, Adrian John Fretland, Barry Christopher Jones, Rhys Dafydd Owen Jones

Curr Drug Metab· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes.
Delilah F G Hendriks, Sabine U Vorrink, Tomas Smutny, Sarah C Sim, Åsa Nordling, Barry C Jones

Clin Pharmacol Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug metabolite identification using ultrahigh-performance liquid chromatography-ultraviolet spectroscopy and parallelized scans on a tribrid Orbitrap mass spectrometer.
Stephen D Wilkinson, Scott Martin, Alexandra L Orton, Roshini Markandu, Barry C Jones

Rapid Commun Mass Spectrom· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Investigation into the Prediction of the Plasma Concentration-Time Profile and Its Interindividual Variability for a Range of Flavin-Containing Monooxygenase Substrates Using a Physiologically Based Pharmacokinetic Modeling Approach.
Venkatesh Pilla Reddy, Barry C Jones, Nicola Colclough, Abhishek Srivastava, Joanne Wilson

Drug Metab Dispos· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP-Mediated Sulfoximine Deimination of AZD6738.
Barry C Jones, Roshini Markandu, Chungang Gu, Graeme Scarfe

Drug Metab Dispos· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Investigation into the Prediction of in Vivo Clearance for a Range of Flavin-containing Monooxygenase Substrates.
Barry C Jones, Abhishek Srivastava, Nicola Colclough, Joanne Wilson, Venkatesh Pilla Reddy

Drug Metab Dispos· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach.
Barry C Jones, Helen Rollison, Susanne Johansson, Kajsa P Kanebratt, Craig Lambert

Drug Metab Dispos· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring concepts of in vitro time-dependent CYP inhibition assays.
David M Stresser, Jialin Mao, Jane R Kenny, Barry C Jones, Kenneth Grime

Expert Opin Drug Metab Toxicol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of PBPK modelling in drug discovery and development at Pfizer.
Hannah M Jones, Maurice Dickins, Kuresh Youdim, James R Gosset, Neil J Attkins, Barry C Jones

Xenobiotica· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.
Hannah M Jones, Iain B Gardner, Wendy T Collard, Phil J Stanley, Penny Oxley, Barry C Jones

Clin Pharmacokinet· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytochrome P450 metabolism and inhibition: analysis for drug discovery.
Barry C Jones, Donald S Middleton, Kuresh Youdim

Prog Med Chem· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point.
Kuresh A Youdim, Richard Lyons, Leon Payne, Barry C Jones, Kenneth Saunders

J Pharm Biomed Anal· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of cytochrome P450: assessment in an immortalized human hepatocyte cell line (Fa2N4) using a novel higher throughput cocktail assay.
Kuresh A Youdim, Christine A Tyman, Barry C Jones, Ruth Hyland

Drug Metab Dispos· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.
Rajaa A Mirghani, Jane Sayi, Eleni Aklillu, Annika Allqvist, Mary Jande, Barry C Jones

Pharmacogenet Genomics· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole.
Chie Emoto, Shigeo Murase, Yasufusa Sawada, Barry C Jones, Kazuhide Iwasaki

Drug Metab Pharmacokinet· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.
J Andrew Williams, Ruth Hyland, Barry C Jones, Dennis A Smith, Susan Hurst

Drug Metab Dispos· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reaction phenotyping in drug discovery: moving forward with confidence?
J Andrew Williams, Susan I Hurst, Jonathan Bauman, Barry C Jones, Ruth Hyland

Curr Drug Metab· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting oral absorption and bioavailability.
Han van de Waterbeemd, Barry C Jones

Prog Med Chem· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)- 5-[2-[(3-substituted)-1-azetidinyl]ethyl]-2-piperidones. 1. Selective antagonists of the neurokinin-2 receptor.
A Roderick MacKenzie, Allan P Marchington, Donald S Middleton, Sandra D Newman, Barry C Jones

J Med Chem· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a combined protein and pharmacophore model for cytochrome P450 2C9.
Marcel J de Groot, Alexander A Alex, Barry C Jones

J Med Chem· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis